Im­mat­ics and Ed­i­tas part­ner on gene edit­ing and T cells; Eye­n­ovia founder to step down from CEO po­si­tion

Two com­pa­nies deeply in­volved in gene edit­ing and T-cells are com­ing to­geth­er in a new deal.

Im­mat­ics and Ed­i­tas Med­i­cine an­nounced Tues­day that they have en­tered in­to a re­search and li­cens­ing agree­ment. The deal will seek to com­bine gam­ma-delta T cell adop­tive cell ther­a­pies and gene edit­ing to de­vel­op med­i­cines for can­cer treat­ment. As part of the li­cens­ing agree­ment, Im­mat­ics gains non-ex­clu­sive rights to Ed­i­tas Med­i­cine’s CRISPR tech­nol­o­gy and in­tel­lec­tu­al prop­er­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.